Healsun Biopharm Funding: $27M Raised, Series C (2023)
Healsun Biopharm is based in Hangzhou, Zhejiang, China. It has raised $27M in total funding. Latest round: Series C.
Healsun Biopharm funding overview
Healsun Biopharm is based in Hangzhou, Zhejiang, China. Healsun Biopharm has raised $27M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series C announced in October 2023. The round record for Healsun Biopharm runs through 2023; nothing later has been disclosed. Investors on record include Shenzhen Kangzhe Pharmaceutical Co., Ltd., Hangzhou Oriental Jiafu Asset Management Co., Ltd., China Medical System Holdings Limited. 3 distinct backers are named across the disclosed rounds.
Healsun Biopharm at a glance
Total raised
$27M
Latest round
Series C
Latest round date
October 2023
Headquarters
Hangzhou, Zhejiang, China
Notable investors
Shenzhen Kangzhe Pharmaceutical Co., Ltd., Hangzhou Oriental Jiafu Asset Management Co., Ltd., China Medical System Holdings Limited
Frequently asked about Healsun Biopharm funding
How much has Healsun Biopharm raised?
Healsun Biopharm has raised $27M in total disclosed funding across the rounds on record.
Who has invested in Healsun Biopharm?
Shenzhen Kangzhe Pharmaceutical Co., Ltd., Hangzhou Oriental Jiafu Asset Management Co., Ltd., China Medical System Holdings Limited are named among the investors backing Healsun Biopharm.
What was the latest Healsun Biopharm funding round?
The most recent disclosed round is a Series C, announced in October 2023.
Where is Healsun Biopharm based?
Healsun Biopharm is based in Hangzhou, Zhejiang, China.
When did Healsun Biopharm last raise?
The last disclosed Healsun Biopharm round closed in October 2023 at Series C.
Healsun Biopharm totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Hangzhou below to benchmark round size and investor mix.
